Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied due to quantity / dose limits by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

## Aetna Quantity Limits on Tirzepatide: The Titration Schedule Is the Whole Battle

Quantity-limit (QL) denials on tirzepatide are not coverage denials in the conventional sense — they are utilization-management edits administered by CVS Caremark as Aetna's PBM, enforcing the FDA-labeled titration schedule against the pen count dispensed per 28-day fill. Aetna Precertification/QL Form 5496-C (Mounjaro/Zepbound) caps fills at one carton (four 0.5 mL pens) per 28 days and locks dose escalation to the package insert: 2.5 mg starter for 4 weeks, then 5 mg, with increases in 2.5 mg increments no sooner than every 4 weeks. A QL reject (NCPDP reject code 76 or 569) almost always traces to one of three triggers: (1) an early refill before the 28-day clock, (2) a dose jump that skips the 4-week interval (e.g., 5 mg → 10 mg at week 6), or (3) a prescriber writing two cartons per month to compensate for a missed titration step.

Because this is a QL edit and not a medical-necessity denial, the appeal pathway runs through CVS Caremark's Pharmacy Prior Authorization queue, not Aetna medical PA. Submit the QL override on Caremark's Mounjaro/Zepbound criteria form (the same 5496-C, with the QL exception box checked) and attach: (a) titration log showing dose, date dispensed, and tolerability notes for each prior step; (b) chart documentation of HbA1c ≥6.5% (the threshold Caremark applies for T2DM coverage); and (c) clinical rationale if you are requesting a non-label quantity (e.g., split-dose protocol for GI-intolerant patients held at 7.5 mg for 8 weeks instead of 4).

For fully-insured ERISA plans, a QL edit is a non-quantitative treatment limitation subject to 29 CFR §2560.503-1 disclosure rules — you are entitled to the specific clinical criteria and the comparative analysis Caremark used to set the limit. Request both in writing; Caremark's standard denial letter omits the criteria URL and that omission is itself an ERISA full-and-fair-review defect. For Aetna Medicare Part D, QL exceptions are governed by 42 CFR §423.578(b) — the prescriber's supporting statement must assert that the preferred quantity "would not be as effective" or "would have adverse effects," and Aetna must decide within 72 hours (24 hours expedited).

If the denial is for Zepbound (obesity indication) on a Part D plan, stop appealing on QL grounds — 42 USC §1395w-102(e)(2)(A) statutorily excludes weight-loss drugs from Part D, so the real denial is categorical exclusion masquerading as a QL edit. Pivot to commercial coverage or manufacturer savings.

Tactical tip: Before filing the override, pull the Caremark dispensing history via the member portal and confirm the fill dates align with a clean 28-day cadence going back 12 weeks. A single early fill from a vacation supply request resets the QL clock and is the most common silent denial trigger — fix the pharmacy record first, then appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.